

Received: 2002.06.24  
Accepted: 2003.06.25  
Published: 2003.11.03

## Dialysis adequacy, residual renal function and serum concentrations of selected low molecular weight proteins in patients undergoing continuous ambulatory peritoneal dialysis

### Authors' Contribution:

- A** Study Design
- B** Data Collection
- C** Statistical Analysis
- D** Data Interpretation
- E** Manuscript Preparation
- F** Literature Search
- G** Funds Collection

Tomasz Stompór<sup>1</sup>, Władysław Sułowicz<sup>1</sup>, Tomasz Anyszek<sup>2</sup>,  
Beata Kuśniercz<sup>2</sup>, Danuta Fedak<sup>2</sup>, Jerzy Naskalski<sup>2</sup>

<sup>1</sup> Department of Nephrology, College of Medicine, Jagiellonian University, Cracow, Poland

<sup>2</sup> Chair of Clinical Biochemistry, Jagiellonian University, Cracow, Poland

Source of support: none.

<b>Background:</b>	<b>Summary</b> Low molecular weight proteins (LMWP) are considered uremic toxins. There is controversy whether in peritoneal dialysis (PD) the elimination of these toxins is influenced mainly by dialysis or by residual renal function (RRF).
<b>Material/Methods:</b>	The aim of our study was to evaluate the relationship between serum levels of selected LMWPs, dialysis adequacy, and RRF in PD patients. 27 stable subjects were studied, mean age 50±11, dialyzed for a median period of 10 months. Serum activity of acid RNA-se and alkaline RNA-se was measured by spectrophotometry, and serum alpha <sub>1</sub> -microglobulin (α <sub>1</sub> M) concentration by ELISA. Kt/V and weekly creatinine clearance (wCl <sub>Cr</sub> ) were assessed as adequacy indices (both as the sum of renal and dialysis components) and RRF as the mean of residual urea and creatinine clearances.
<b>Results:</b>	Significant inverse correlations were found between RRF and α <sub>1</sub> M level, as well as alkaline RNA-se activity (p<0.0001). A similar relationship was found for residual Kt/V (p<0.0001 for α <sub>1</sub> M and alkaline RNA-se). There was no significant correlation between acid RNA-se activity and any tested parameter of adequacy. When the cutoff points of wCl <sub>Cr</sub> = 60 L/week/m <sup>2</sup> , total Kt/V = 2.0, or RRF=2.0 ml/min were used, we found α <sub>1</sub> M level and alkaline RNA-se activity to be significantly lower in patients with higher values of the respective parameters.
<b>Conclusions:</b>	RRF plays an important role in elimination of LMWP in PD. The activity of alkaline RNA-se and acid RNA-se behaves differently in these patients.
<b>key words:</b>	uremic toxins • peritoneal dialysis • acid RNA-se • alkaline RNA-se
<b>Full-text PDF:</b>	<a href="http://www.MedSciMonit.com/pub/vol_9/no_11/2878.pdf">http://www.MedSciMonit.com/pub/vol_9/no_11/2878.pdf</a>
<b>Word count:</b>	2101
<b>Tables:</b>	3
<b>Figures:</b>	–
<b>References:</b>	28
<b>Author's address:</b>	Tomasz Stompór, MD, Department of Nephrology, Jagiellonian University, ul. Kopernika 15c, 31-501 Kraków, Poland, email: stompin@mp.pl

## BACKGROUND

Uremic toxemia occurs due to the effect of catabolite accumulation, which adversely affects the function of various organs and tissues. These substances may be divided into several categories. According to their molecular weights, they are classified as low (<300), middle (300–15,000) and high molecular weight uremic toxins (>15000) [1,2]. The urea and creatinine concentrations or urea and creatinine elimination rates (clearances) are generally used as a common denominators of uremic toxin accumulation. The same indices are used to assess dialysis adequacy. Though a great amount of data has demonstrated a relationship between the patients' clinical outcome, normalized clearance of urea (Kt/V), and weekly creatinine clearance ( $Cl_{Cr}$ ) [3–6], the importance for the development of toxemia of many individual compounds accumulating in the plasma of end-stage renal disease patients is still unknown. Thus particular interest has been focused on the group of low molecular weight proteins (LMWPs) accumulating in plasma, along with gradual loss of renal function, remaining extremely elevated in patients maintained on renal replacement therapy [7–11]. As shown by Jung et al., the accumulative increase of plasma ribonuclease is a more sensitive indicator of renal function impairment than creatinine [12]. A decrease in glomerular filtration is the most common cause of elevated plasma  $\alpha_1$  microglobulin ( $\alpha_1M$ ). Others authors suggest that the measurement of  $\alpha_1M$  may be helpful in the so-called creatinine-blind range of glomerular filtration rate (GFR) decrease.  $\alpha_1M$  is probably superior to  $\beta_2$ -microglobulin or retinol-binding protein to measure loss of renal function, although probably cystatin C elimination measurement would be best for this purpose [13]. The elimination of  $\alpha_1M$  with urine also appears to be a useful diagnostic tool of subclinical nephropathy, as a marker of early renal damage, for example in patients with stable angina without symptoms of kidney disease [14]. On the other hand, serum  $\beta_2$ -microglobulin concentration is related not only to the current level of renal function, but also to many pathologies associated with inflammatory process or cellular damage, since this protein is one of the domains of histocompatibility class I HLA antigens [15,16].

The LMWP accumulation process may serve as a model of uremic toxin accumulation independently of the urea and creatinine removal rate. Urea and creatinine elimination are assessed in the evaluation of dialysis adequacy because of the simplicity, but the serum levels of these solutes do not reflect the state of toxemia, as they are not toxic themselves. It would be much more appropriate to assess other compounds of larger molecular weight, but such methods have not been developed as routine procedures for everyday clinical practice.

The aim of our study was to make a cross-sectional measurement of serum levels of selected LMWPs in patients on continuous ambulatory peritoneal dialysis (CAPD), and to evaluate the potential impact of residual renal function and dialysis adequacy on serum levels of these proteins. The most important issue in this study was to assess the contribution and importance of both residual diuresis and peritoneal dialysis to the elimination of LMWPs.

## MATERIAL AND METHODS

27 clinically stable CAPD patients were enrolled into the study: 13 females, 14 males, ranging in age from 22 to 74 years (mean  $50 \pm 11$  years) dialyzed for a median period of 10 months (range 1–56 months). The etiology of end-stage renal disease included primary glomerulopathy in 13 patients, polycystic kidney disease in 2, chronic pyelonephritis in 1 and amyloidosis in 1. In 10 cases no primary diagnosis of chronic nephropathy had been established, mainly due to late referral to the renal unit.

Samples for RNA-ses were centrifuged at 1000 g, 4°C. RNA-se activity was determined from 20- $\mu$ l serum samples incubated with 180  $\mu$ l of 100 mmol/l sodium phosphate buffer (8.5 ml of 0.2 M.  $NaH_2PO_4$  plus 91.5 ml of 0.2 M.  $Na_2HPO_4$  – pH 7.8 for alkaline RNA-se or 68.5 ml of 0.2 M.  $NaH_2PO_4$  plus 31.5 ml of 0.2 M.  $Na_2HPO_4$  – pH 6.5 for acid RNA-se), plus 200  $\mu$ l of RNA substrate (6 g/l RNA in sodium phosphate buffer, pH 7.8 for alkaline RNA-se or pH 6.5 for acid RNA-se). After 60 minutes of incubation the RNA precipitating agent (600  $\mu$ l of 6 mmol/l uranyl acetate) was added. The samples were centrifuged at 4°C. 100  $\mu$ l of clear supernatant was taken off and diluted in 1.4 ml of distilled water. Then spectrometric absorption at 260 nm was determined. A blank assay was prepared exactly as the samples, omitting the incubation step. Each test was performed in duplicate, and final RNA-se activity was calculated as a mean value.

All values were expressed in arbitrary units. One unit of RNA-se activity was the amount of hydrolyzed RNA which under standard conditions liberates low molecular RNA-degradation products ( $A_{260} = 0.360 \times \text{cm}^{-1}$ ). RNA-se activity was calculated by equation (1):

$$RNA-se (U/l) = [(A_{260} - 0.02) / 0.316]^2 \quad (1)$$

This equation shows the relationship between RNA-se concentration and the increased light absorption at 260 nm.

Acid and alkaline RNA-se isoenzymes were assayed by determining the total RNA-se activity at pH 6.5 (RNA-se<sub>6.5</sub>) and pH 7.8 (RNA-se<sub>7.8</sub>), and then further calculations were performed using equations (2) and (3):

$$alkaline\ RNA-se = 1.11 \times RNA-se_{7.8} - 0.67 \times RNA-se_{6.5} \quad (2)$$

$$acid\ RNA-se = RNA-se_{6.5} - 0.17 \times alkaline\ RNA-se \quad (3)$$

The origin of all three equations used here has been described in detail elsewhere [10,17].

$\alpha_1M$  was determined in serum using the nephelometric method (Behring Nephelometer, Behringwerke AG, Marburg, Germany). Intra-assay variability for this assay was less than 5%.

Dialysis adequacy was assessed using the sum of dialysis and residual urea and creatinine clearances, standardized to distribution volume (Kt/V) or body surface area

**Table 1.** The mean/median values and SD/range of the serum levels/activity of the tested low molecular-weight proteins, and dialysis adequacy parameters.

	Unit	Mean/Median	SD/Range
$\alpha_1$ M	mg/l	29.4	14.8
Acid RNA-se	U/l	0.29	0.038–0.78
Alk. RNA-se	U/l	1.56	0.42
wCl <sub>Cr</sub> total	l/week/1.73m <sup>2</sup>	69.5	40.0–127.1
wCl <sub>Cr</sub> dial.	l/week/1.73m <sup>2</sup>	37.6	9.9
Cl <sub>Cr</sub> res	ml/min	2.81	0–9.24
Kt/V total	–	1.96	0.35
Kt/V dial.	–	1.4	0.39
Kt/V res.	–	0.63	0–1.7
RRF	ml/min	2.29	0–7.07

Abbreviations: as in the text

(wCl<sub>Cr</sub>). Serum, urine and dialysate urea and creatinine levels were measured using a Hitachi 917 analyzer. Urine and dialysate urea and creatinine were measured in 24-hour collections. Fasting blood was taken in the morning the day after collection was completed. Adequacy indices (Kt/V, wCl<sub>Cr</sub>) were calculated using the licensed, commercially available software package Nephron for Windows (DDPS, Cracow, Poland). This program utilizes anthropometric Watson formulas for distribution volume calculations. RRF was expressed as the mean of the sum of residual renal urea and creatinine clearances. In addition, the dialysate-to-plasma creatinine (D/P<sub>Creat</sub>) ratio in the standardized Peritoneal Equilibration Test (PET) was calculated for every subject, according to the method described by Twardowski [18].

### Statistical analysis

Statistical analysis of the data was performed with Statistica 5.1 software (StatSoft Inc, Tulsa, Oklahoma, USA). Shapiro-Wilk's *W*-test of normality was used for data distribution analysis. All variables with normal distribution were presented as mean  $\pm$ SD; those with non-normal distribution, as median and range. The t-Student test for inter-group comparisons and Pearson test for correlations between variables were used for normally distributed data, whereas the *U* Mann-Whitney and *R* Spearman test, respectively, were applied to non-normally distributed data. We considered a *p* value less than 0.05 to be statistically significant.

### RESULTS

The parameters analyzed in the present study are summarized in Table 1. The median value of D/P<sub>Creat</sub> was 0.56 (range 0.35–0.8), with 14 patients classified as Low/Low-Average Transporters (L/LA, median 0.51; range 0.35–0.56), and the remaining 13 as High/High-Average Transporters (H/HA, median 0.76; range 0.68–0.8).

Significant negative correlations were demonstrated for RRF and the  $\alpha_1$ M level, as well as RRF and alkaline RNA-se serum activity ( $R=-0.83$ ;  $p<0.0001$  and  $R=-0.73$ ;  $p<0.0001$ , respectively; *R* Spearman rank

test). A similar relationship was found for residual Kt/V ( $R=-0.48$ ;  $p<0.0001$  for  $\alpha_1$ M and  $r=-0.79$ ;  $p<0.0001$  for alkaline RNA-se). Inverse relationships were also found for the level/activity of both mentioned proteins and residual diuresis volume ( $R=-0.76$ ;  $p<0.0001$  for  $\alpha_1$ M and  $R=-0.69$ ;  $p<0.0001$  for alkaline RNA-se), as shown in Table 2.

The total values of both wCl<sub>Cr</sub> and Kt/V depended strongly on residual components of these adequacy parameters ( $r=0.88$ ;  $p<0.0001$  for total and residual wCl<sub>Cr</sub>, and  $r=0.64$ ;  $p<0.005$  for total and residual Kt/V), whereas no relationship was observed between total and dialytic components.

No statistically significant correlation was found between acid RNA-se activity and any tested parameter of adequacy. It is worth nothing that there were positive correlations between  $\alpha_1$ M, alkaline RNA-se and dialytic components of both analyzed adequacy parameters.  $\alpha_1$ M serum level and alkaline RNA-se but not acid RNA-se activity were proportional to dialysis treatment duration (Table 2).

Dividing our patients according to the cutoff values of a total wCl<sub>Cr</sub> of 60 L/week/m<sup>2</sup>, total Kt/V of 2.0 or RRF of 2.0 ml/min, we found  $\alpha_1$ M serum level and alkaline RNA-se activity to be significantly lower in patients with values above the respective cutoff lines (Table 3). No differences were found in serum concentration or activity of tested LMWPs between L/LA vs. H/HA transporters.

### DISCUSSION

The molecular weight of serum RNA-ses fits in the range between 8,500 and 33,000, whereas the molecular weight of  $\alpha_1$ M is equal to 30,000. In comparison,  $\beta_2$ -microglobulin, the protein usually used to assess the accumulation of larger molecular size toxins, has a molecular weight of 11,800. Thus the analyzed proteins should be classified into the group of toxins with the largest molecular size [1].

The results obtained in this study indicate that serum concentrations of the selected low molecular weight proteins directly depend upon residual diuresis. Both  $\alpha_1$ M level and alkaline RNA-se activity correlated inversely with the values of total and residual components of both tested indices of adequacy (residual Kt/V and wCl<sub>Cr</sub>). Differences in elimination of substances with higher molecular weight in dialyzed patients with preserved residual diuresis in comparison to anuric individuals have already been demonstrated for  $\beta_2$ -microglobulin [19,20]. Not only  $\beta_2$ -microglobulin, but also RNA-se seem to be good markers of decreasing glomerular filtration rate [12,21]. It has been suggested that RNA-se may be a very useful and sensitive indicator of decreased renal function in patients who still maintain normal creatinine clearance [12].

Interestingly, serum levels of  $\alpha_1$ M and alkaline RNA-se correlated directly with the dialytic components of both analyzed adequacy indices. This phenomenon may be

**Table 2.** Correlation between  $\alpha_1$ M serum level, alkaline RNA-se activity and parameters of dialysis adequacy (*R* Spearman rank test, unless stated otherwise).

		CAPD duration	RRF	Kt/V dial.	Kt/V res.	Kt/V total	wClCr dial.	wClCr res.	wClCr total
$\alpha_1$ M	R=	0.57	-0.83	0.64	-0.84	-0.62	0.66	-0.82	-0.64
	p<	0.01	0.0001	0.001	0.0001	0.005	0.001	0.0001	0.005
Alk.	R=	0.57	-0.73	0.46*	-0.79	-0.63*	0.39*	-0.84	-0.64
	p<	0.01	0.0001	0.05	0.0001	0.001	0.05	0.0001	0.05

\* Pearson's test;

Abbreviations: as in the text

**Table 3.** Comparison of serum level/activity of tested LMWPs among patients with higher and lower values of total wClCr, Kt/V and RRF.

	$\alpha_1$ M (mg/l)	Alk. RNA-se (U/l)
wClCr total >60 (L/week/1.73m <sup>2</sup> ) (N=14)	19.45 (11.6–32.3)	1.32±0.28
wClCr total <60 (L/week/1.73m <sup>2</sup> ) (N=13)	43.9 (15.7–60.6)	1.82±0.41
	p<0.01*	p<0.001**
Kt/V >2.0 (N=13)	19.0 (11.6–53.5)	1.32±0.32
Kt/V <2.0 (N=14)	39.4 (27.3–60.6)	1.78±0.39
	p<0.005*	p<0.005**
RRF >2.0 (ml/min) (N=14)	18.5 (11.6–32.3)	1.34±0.28
RRF <2.0 (ml/min) (N=13)	43.9 (27.3–60.6)	1.84±0.38
	p<0.001*	P<0.0005**

\* U Mann-Whitney test;

\*\* t-Student test;

Abbreviations: as in the text

explained by the well-known fact that the dialysis dose increases following RRF decline, as do the dialytic components of Kt/V or wClCr. Our findings may suggest that an increased dialysis dose cannot replace residual renal function in terms of LMWP removal.

As shown in our study, acid RNA-se behaves in a different mode compared to alkaline RNA-se. This may be explained by the differing origin of these two enzymes. Acid RNA-se is mainly derived from leukocytes, and its release during dialysis may reflect bioincompatibility of renal replacement therapy, as has been shown for hemodialysis (HD) [22,23]. It has been demonstrated that a HD session leads to increased activity of different enzymes, including acid RNA-se, mainly due to leukocyte degranulation on dialysis membranes [11,24]. On the other hand, alkaline RNA-se is predominantly a pancreatic enzyme, and its release is probably less influenced by dialysis itself, hence the effect of its removal may be demonstrated. CAPD is a continuous mode of dialysis with relatively steady-state levels of various solutes. However, the continuous stimulation of leukocytes by bioincompatible dialysis fluid resulting in the prolonged release of leukocyte enzymes (with a rate

comparable to their elimination) may be taken under consideration.

Many data indicate that residual renal function is important for obtaining the desired values of dialysis adequacy indices, and its impact on the clinical outcome of renal replacement therapy is well documented [25–27]. Contemporary methods of dialysis allow replacement of reduced kidney function. It is beyond doubt that an increasing dialysis dose allows for efficient elimination of small solutes to an extent compensating for deteriorating renal function. It seems, however, that this treatment cannot compensate for lost renal elimination of substances with higher molecular weights, responsible for the development of uremic toxemia. This is due to the lack of the fundamental metabolic function of the kidneys in the elimination of these substances, which also includes protein catabolism. In this respect, the question as to whether deteriorating renal function can be replaced with increasing dialysis dose remains open.

Based on the results of the latest large-scale prospective studies, which failed to demonstrate any substantial impact of small solute clearance on long-term survival, we believe that the assessment of the serum concentration of substances with larger molecular weight appears to be more appropriate to describe uremic toxemia [28].

## CONCLUSIONS

The results of our study seem to indicate that serum levels or enzymatic activity of the selected small-molecule proteins depend on residual renal function. This means that the assessment of peritoneal dialysis efficacy by reference to the elimination of these substances alone, particularly among patients without residual renal function, does not reflect the actual accumulation of toxic metabolites. It should be noted that the behavior of acid and alkaline RNA-se activity is different, with no relationship between acid RNA-se and RRF or dialysis adequacy.

## REFERENCES:

1. Vanholder R, De Smet R: Pathophysiologic effects of uremic retention solutes. *J Am Soc Nephrol*, 1999; 10: 1815-1823
2. Vanholder R, De Smet R, Voegelere P, Ringoir S: Middle molecules: toxicity and removal by hemodialysis and related strategies. *Artif Organs*, 1995; 19: 1120-1225
3. Selgas R, Bajo MA, Fernandez-Reyes MJ et al.: An analysis of adequacy of dialysis in a selected population on CAPD for over 3 years: the influence of urea and creatinine kinetics. *Nephrol Dial Transplant*, 1993; 8: 1244-1253

4. Teehan BP, Schleifer CR, Brown JM et al.: Urea kinetic modeling and clinical outcome. A five year longitudinal study. In: Khanna R (ed.) *Advances in continuous ambulatory peritoneal dialysis*. Perit Dial Bull Inc. Toronto, 1990; 6: 181-185
5. Keshaviah PR, Nolph KD, Van Stone JC: The peak concentration hypothesis. A urea kinetic approach to comparing the adequacy of continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis. *Perit Dial Int*, 1989; 9: 257-260
6. Genestier S, Hedelin G, Schaffer P, Faller B: Prognostic factors in CAPD: a retrospective study of 10-year period. *Nephrol Dial Transplant*, 1995; 10: 1905-1911
7. Rabin E, Algom D, Freedman M et al.: Ribonuclease activity in renal failure. Evidence of toxicity. *Nephron*, 1991; 27: 254-259
8. Kult J, Dragoun G: Low molecular serum proteins in uremic patients. In: Heidland A, Hennemann H, Kult J. (Ed.) *Renal insufficiency*. Georg Thiemes Publishers, Stuttgart, 1976; 115-120
9. Weber M, Scholtz P, Stibbe W, Scheler F: Alpha<sub>1</sub>-microglobulin in the urine and serum in proteinuria and kidney insufficiency. *Klin Wochenschr*, 1985; 63: 711-717
10. Naskalski JW, Ekiert - Kubinyi M, Krzemień D: Serum ribonuclease activity in dialyzed patients with terminal renal failure. *Acta Med Pol*, 1986; 27: 3-4
11. Naskalski J, Krzemień D: Accumulation of low molecular weight proteins in patients treated with hemodialysis. *Nephron*, 1993; 63: 484
12. Jung K, Schulze BD, Sydow K et al.: Diagnostic value of low-molecular mass proteins in serum for the detection of reduced glomerular filtration rate. *J Clin Chem Clin Biochem*, 1987; 25: 499-503
13. Itoh Y, Enomoto H, Takagi K, Kawai T: Clinical usefulness of serum  $\alpha$ 1-microglobulin as a sensitive indicator for renal insufficiency. *Nephron*, 1983; 35: 211-212
14. Marczewski KT, Krawczyk W, Grzywina R et al.: Particular fractions of microproteinuria in patients with stabile angina pectoris and without a clinical nephropathy. *Med Sci Monit*, 2000; 6: 93-5
15. Lapinski TW, Kot A, Prokopowicz D: Concentration of  $\beta_2$ -microglobulin and percentage of CD4 lymphocytes in peripheral blood in patients with chronic HCV infection during IFN- $\alpha$  therapy. *Med Sci Monit*, 2002; 8: CR538-42
16. Yavuz S, Ayabakan N, Goncu MT, Ozdemir IA: Effect of combined dopamine and diltiazem on renal function after cardiac surgery. *Med Sci Monit*, 2002; 8: P145-50
17. Naskalski JW, Celiński A: Determining of acid and alkaline ribonuclease in human serum and urine. *Math Med Pol*, 1992; 78: 107-110
18. Twardowski ZJ, Nolph KD, Khanna R: Peritoneal Equilibration Test. *Perit Dial Bull*, 1987; 7: 138-147
19. Montenegro J, Martinez I, Saracho R, Gonzales R: Beta<sub>2</sub>-microglobulin in CAPD. *Adv Perit Dial*, 1992; 8: 369-372
20. Amici G, Virga G, Da Rin G et al.: Serum beta-2-microglobulin level and residual renal function in peritoneal dialysis. *Nephron*, 1993; 65: 469-471
21. Schardijn GHC, van Eps LWS:  $\beta_2$ -microglobulin: its significance in the evaluation of renal function. *Kidney Int*, 1987; 32: 635-641
22. Horl W, Johum M, Heidland A, Fritz H: Release of granulocyte proteinase during hemodialysis. *Am J Nephrol*, 1983; 3: 213-217
23. Horl W, Schafer RM, Heidland A: Effect of different dialysers on proteinases and proteinase inhibitors during hemodialysis. *Am J Nephrol*, 1985; 5: 320-325
24. Luciak M, Tchorzewski H, Trznadel K: Release of neutrophil granule factors during early periods of hemodialysis. A possible cause of haemodialysis neutropenia. *Nephron*, 1984; 37: 30-34
25. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous ambulatory peritoneal dialysis: association with clinical outcomes *J Am Soc Nephrol*, 1996; 7: 198-207
26. Lameire NH: The impact of residual renal function on the adequacy of peritoneal dialysis. *Nephron*, 1997; 77: 13-28
27. Lopez-Menchero R, Miguel A, Garcia-Ramon R et al.: Importance of residual renal function in continuous ambulatory peritoneal dialysis: its influence on different parameters of renal replacement treatment. *Nephron*, 1999; 83: 219-225
28. Paniagua R, Amato D, Vonesh E et al.: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. *J Am Soc Nephrol*, 2002; 13: 1307-1320